13054-81-4

Basic information

• Product Name: 4-CHLORO-3,5-HEPTANEDIONE
• Synonyms: 4-CHLORO-3,5-HEPTANEDIONE;3,5-Heptanedione, 4-chloro-;4-Chloroheptane-3,5-dione
• CAS NO: 13054-81-4
• Molecular Formula: C7H11ClO2
• Molecular Weight: 162.61
• Mol File: 13054-81-4.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-CHLORO-3,5-HEPTANEDIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-3,5-HEPTANEDIONE(13054-81-4)
• EPA Substance Registry System: 4-CHLORO-3,5-HEPTANEDIONE(13054-81-4)

Safety Data

• Hazardous Substances Data: 13054-81-4(Hazardous Substances Data)

Upstream product

• 7424-54-6 3,5-heptanedione 

Downstream Products

• 1194545-34-0 C₁₃H₁₅FO₃ 
• 1194545-30-6 C₁₃H₁₄Cl₂O₃ 
• 1194545-25-9 C₁₃H₁₅ClO₃ 
• 1194545-33-9 C₁₃H₁₅FO₃ 
• 1194545-29-3 C₁₃H₁₄Cl₂O₃ 
• 1194545-31-7 C₁₃H₁₄Cl₂O₃ 
• 1194545-36-2 C₁₃H₁₄F₂O₃ 
• 473923-53-4 4-(3-Cyanophenoxy)-3,5-heptanedione 
• 1194545-38-4 C₁₃H₁₄F₂O₃ 
• 1194545-27-1 C₁₃H₁₄Cl₂O₃ 
• 1194545-40-8 C₁₃H₁₄F₂O₃ 
• 1194545-37-3 C₁₃H₁₄F₂O₃ 
• 1194545-39-5 C₁₃H₁₄F₂O₃ 
• 1194545-35-1 C₁₃H₁₄F₂O₃ 

Relevant articles and documents

Preparation method of dichloro dialkyl fumaronitrile

The preparation method comprises the following steps: I raw materials are taken as raw materials, and chlorine or N - chlorosuccinimide is used as a chlorination reagent for chlorination reaction to generate compound II. The condensation reaction of compound II with cyanoacetamide is carried out under the action of a base to give compound III. The compound III is chlororeacted with phosphorus oxychloride to give a dichloro dialkyl nicotinonitrile. The preparation method avoids the use of sulfonyl chloride as a chlorination reagent, thereby avoiding the generation of sulfur dioxide tail gas, and preventing the generated acid waste gas from corroding equipment and the like.

Pyrazole NNRTIs 4: Selection of UK-453,061 (lersivirine) as a Development Candidate

We prepared three discreet cohorts of potent non-nucleoside HIV reverse transcriptase inhibitors (NNRTIs) based on the recently reported 3-cyanophenoxypyrazole lead 3. Several of these compounds displayed very promising anti-HIV activity in vitro, safety,

COMPOUNDS USEFUL IN THERAPY

Compounds of formula (I), or a pharmaceutically acceptable derivative thereof, wherein R1 and R3 independently represent H, C1-6alkyl, C3-8cycloalkyl, or halogen; R2 represents C1-6alkyl, CF3 or aryl; a represents 1 or 2; R4, R5, R7 and R8 independently represent H, C1-6alkyl, C1-6alkyloxy, CN or halogen, or R4 and R5, or R7 and R8, together with the ring to which they are attached form an aryl or heterocyclic fused ring system; X represents C or N; Y represents CH2 or O; R6 represents H, CN or halo provided that, when X represents N, R6 is absent. The compounds are useful for treating endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.